BackContineum Therapeutics Overview
Contineum Therapeutics Inc. - Ordinary Shares - Class A

Contineum Therapeutics Target Price

See Contineum Therapeutics's analyst price targets ($16) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$14.53

Average Target Price

$16.0010.1% upside

1 analysts in the last 4 months

High: $16 | Low: $16

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-05-14Morgan Stanley$1610.1% upsideOpen
2026-01-08Morgan Stanley$143.6% downsideOpen
2025-11-24Robert W. Baird$143.6% downsideOpen
2025-11-21RBC CapitalBrian Abrahams$2251.4% upsideOpen
2025-09-25Leerink Partners$2037.6% upsideOpen
2025-03-07Robert W. Baird$1610.1% upsideOpen
2024-10-21Robert W. BairdJoel Beatty$32120.2% upsideOpen
2024-04-30RBC CapitalBrian Abrahams$30106.5% upsideOpen
2024-04-30Stifel NicolausPaul Matteis$2999.6% upsideOpen

Contineum Therapeutics (CTNM) FAQ

Contineum Therapeutics (CTNM) currently reports a target price of $16. Use the charts on this page to explore Contineum Therapeutics's target price history and peer comparisons.

Analysts' average 12-month price target for Contineum Therapeutics is $16, about 10.1% upside from the current share price of $14.53. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $16, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Contineum Therapeutics, and consider following CTNM for alerts when major investors trade the stock.